

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.*

WORLD HEALTH ORGANIZATION  
TECHNICAL REPORT SERIES

No. 317

# CHEMOTHERAPY OF BILHARZIASIS

## Report of a WHO Scientific Group

|  | Page |
|--|------|
| 1. Introduction . . . . .  | 3    |
| 2. Sensivity of infection to chemotherapy . . . . .  | 4    |
| 3. Pathogenesis in relation to chemotherapy . . . . .  | 7    |
| 4. Mode of antischistosomal action of antimonials . . . . .  | 11   |
| 5. The effects of antimonials on the cardiovascular system and gastro-intestinal functions . . . . . | 19   |
| 6. Distribution of administered antimony in host and parasite . . . . .                              | 25   |
| 7. Review of antimonials and other antischistosomal drugs . . . . .                                  | 27   |
| 8. Evaluation of treatment . . . . .   | 30   |
| 9. Clinical evaluation of drugs . . . . .  | 32   |
| 10. Recommendations . . . . .  | 33   |
| Annex 1. Trials of antischistosomal drugs . . . . .  | 38   |
| Annex 2. The investigator and the drug supplier . . . . .  | 62   |
| Annex 3. The reference drug . . . . .  | 66   |
| Annex 4. Specifications for examination of patients at centres . . . . .                             | 67   |
| Annex 5. Toxic effects of drugs under test . . . . .   | 70   |

WORLD HEALTH ORGANIZATION

GENEVA

1966